Regulatory Roundup: FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin
FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin.
FDA Commissioner Margaret Hamburg held a special press briefing last week on Genentech’s Avastin drug and its indications for metastatic breast cancer. She announced that the agency is revoking that indication based on FDA follow-up studies which did not show promising results. See related blog and press release.
Recent Videos
Related Content
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025Article
The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
